Lazaridis K, Evaggelakou P, Bentenidi E, Sideri A, Grapsa E, Tzartos S J
Hellenic Pasteur Institute, GR11521 Athens, Greece.
Department of Nephrology, Aretaieion Hospital, Athens, Greece.
J Neuroimmunol. 2015 Jan 15;278:19-25. doi: 10.1016/j.jneuroim.2014.12.001. Epub 2014 Dec 3.
Myasthenia gravis (MG) is usually caused by antibodies against the muscle acetylcholine receptor (AChR). Plasmapheresis and immunoadsorption are often used to treat non-responsive patients. Antigen-specific immunoadsorption would remove only the pathogenic autoantibodies reducing side-effects. We expressed AChR extracellular domain mutants for use as specific adsorbents, and characterized them. Antigenicity and capacity for autoantibody binding were improved compared to the wild-type proteins. Adsorption appeared to be fast, as high plasma flow-rates could be applied. The bound autoantibodies were eluted repeatedly, allowing column reuse, without compromise in efficiency. Overall, the adsorbents were specific, efficient and suitable for use in therapy.
重症肌无力（MG）通常由针对肌肉乙酰胆碱受体（AChR）的抗体引起。血浆置换和免疫吸附常用于治疗无反应的患者。抗原特异性免疫吸附仅会去除致病性自身抗体，从而减少副作用。我们表达了AChR细胞外结构域突变体用作特异性吸附剂，并对其进行了表征。与野生型蛋白相比，其抗原性和自身抗体结合能力得到了改善。由于可以应用高血浆流速，吸附似乎很快。结合的自身抗体可被反复洗脱，使柱得以重复使用，而不会影响效率。总体而言，这些吸附剂具有特异性、高效性且适用于治疗。
